Lang Matthew 4

4 · Structure Therapeutics Inc. · Filed Apr 23, 2026

AI-generated summary of this filing

Updated Apr 23, 2026

Structure Therapeutics COO Matthew Lang Receives RSU/Derivative Awards

What Happened

Matthew Lang, Chief Operating Officer and General Counsel of Structure Therapeutics (GPCR), received two stock-based awards on April 15, 2026 totaling 408,390 shares: 184,614 shares (RSUs) and 223,776 shares listed as a derivative award. Both grants show $0.00 as the acquisition price (no cash paid at grant). The awards are subject to vesting and were reported on a Form 4 filed April 23, 2026.

Key Details

Transaction date: 2026-04-15; Form 4 filed: 2026-04-23 (filed 8 days after the transaction; appears late vs. the usual 2-business-day Form 4 deadline).
Reported amounts: 184,614 shares (RSUs) and 223,776 shares (derivative award) — total 408,390 shares; acquisition price reported as $0.00 for both.
Shares owned after the transaction: not specified in the supplied filing details.
Relevant footnotes from the filing:
- F1: Ordinary shares may be represented by ADSs (each ADS = 3 ordinary shares).
- F2: The 184,614 award represents restricted stock units (RSUs); each RSU is a contingent right to one ordinary share and (per F2) vests 1/4 annually on each anniversary of April 15, 2026, subject to continued service.
- F3/F4: The 223,776 derivative award carries vesting and exercise-price language — F3 notes any option exercise price would equal fair market value on the grant date; F4 indicates one-fourth vests on the first anniversary of April 15, 2026, with the remainder vesting in 36 equal monthly installments thereafter.
No sale or exercise was reported; these are grants/awards, not dispositions.

Context

RSUs and similar derivative awards are common executive compensation; they do not represent immediate cash proceeds and only convert into stock (or ADSs) as they vest.
The derivative award language indicates an instrument tied to future equity (could include options or performance-based shares); the filing shows no immediate exercise or sale.
The April 23 filing date is later than typical Form 4 timing (within 2 business days of the transaction), so the filing appears untimely in this record.

Form 4

Period: 2026-04-15

COO & GC

Transactions

Award
Ordinary Shares
[F1][F2]
2026-04-15+184,614→ 184,614 total
Award
Share option (right to buy)
[F3][F4][F1]
2026-04-15+223,776→ 223,776 total
Exercise: $18.08Exp: 2036-04-14→ Ordinary Shares (223,776 underlying)

Footnotes (4)

[F1]The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
[F2]Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of April 15, 2026, subject to Reporting Person's continued service on such dates.
[F3]The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.
[F4]One-fourth of the shares vest on the first anniversary of April 15, 2026, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

Signature

/s/ Jun Yoon, Attorney-in-Fact|2026-04-22

1 file